The proto-oncogene Bcl6 and its family gene, BAZF, encode a sequence-specific transcriptional repressor which contains the BTB/POZ domain in NH 2 -terminal region and zinc finger motifs in COOH-terminal region. The BTB/POZ domain and the middle portion of Bcl6 and BAZF are known to display transrepressor activity. Since we have identified the identical 17-amino acid (aa) sequence in the middle portion of Bcl6 and BAZF, the 17aa region may be another repressive domain of the middle portion. The reporter gene assay indicates that the 27aa sequence including the 17aa region recruits histone deacetylases to express transrepressor activity. Furthermore, overexpression of Bcl6 or Bcl6(POZ3) (Bcl6 deleted with the BTB/POZ domain) induced apoptosis in NIH3T3 cells, and the apoptosis was inhibited by the addition of histone deacetylase inhibitor in the culture. However, apoptosis was not induced in NIH3T3 cells by overexpression of Bcl6(POZ3) deleted with the 17aa region. These results indicate that the 17aa region in the middle portion of Bcl6 is a functional domain of transrepressor activity and is responsible for inducibility of apoptosis in NIH3T3 cells. ß
Introduction
Chromosomal translocations involving 3q27 have been detected in some non-Hodgkin's lymphomas, particularly in di¡use large B-cell lymphomas [1, 2] . The human proto-oncogene Bcl6 has been identi¢ed from the chromosomal breakpoints [3^5] . The Bcl6 gene encodes a 706-amino acid (aa) nuclear protein which contains a BTB/POZ domain in NH 2 -terminal region and six Kru « ppel-like zinc ¢nger motifs in COOH-terminal region, and Bcl6 acts as a sequence-speci¢c transcriptional repressor [6, 7] . Two noncontiguous regions of Bcl6 (the BTB/POZ domain and the middle portion) express transrepressor activity. We have recently isolated BAZF, a family member of Bcl6, that is also composed of a BTB/ POZ domain and zinc ¢nger motifs, and acts as a sequence-speci¢c transcriptional repressor [8] . Since the 17aa sequence (aa 188 to aa 204) in the middle portion of BAZF is 100% identical to that (aa 370 to aa 386) in the middle portion of Bcl6, the 17aa region may be another repressive domain of Bcl6 and BAZF. Since the BTB/POZ domain of Bcl6 interacts with silencing mediator of retinoid and thyroid receptor protein (SMRT) [9^12] and SMRT forms a repressive complex with histone deacetylase 1 (HDAC 1) [13, 14] , Bcl6 may repress transcription of target genes by locally inducing a repressive (hypoacetylated) chromatin structure through mechanisms involving SMRT recruitment and histone deacetylation. However, molecular mechanisms of transrepression by the middle portion of Bcl6 are not known.
Expression of Bcl6 is ubiquitous [15] and is preferential in germinal center B cells [16, 17] . The germinal center formation is defective in Bcl6-de¢cient (Bcl6 3a3 ) mice [18^20] . Since Bcl6 3a3 mice display massive myocarditis at an adult age, Bcl6 in cardiac myocytes may play a role in protecting cell death of myocytes [21] . Furthermore, in vitro gene transfection experiments demonstrated that overexpression of Bcl6 enhances the viability of di¡erentiating myocytes by preventing them from apoptosis [22] . However, the overexpression induces apoptosis in CV-1 and HeLa cells [23] . Therefore, the role of Bcl6 in protection of apoptosis has remained controversial. Apoptosis is an intrinsic cell suicide program that is universal in metazoan organism [24] . Cells undergoing apoptosis display a series of morphological characteristics including cytoplasm shrinkage, chromatin condensation, membrane blebbing, DNA fragmentation and generation of apoptotic bodies [25] . Apoptosis is an active gene-directed process, and a number of proteins including transcription factors [26^30] can trigger apoptotic cell death. Moreover, apoptosis can be elicited by overexpression of transcriptional repressors [31, 32] . Here we show that the 17aa region in the middle portion of Bcl6 and BAZF expressed transrepressor activity in vitro by recruiting HDACs on target genes. Furthermore, overexpression of Bcl6 or Bcl6(POZ3) (Bcl6 deleted with the BTB/POZ domain) induced apoptosis in NIH3T3 cells and the 17aa region of Bcl6(POZ3) was critical for the induction of apoptosis.
Materials and methods

Assay for transcriptional repressor activity with the luciferase reporter gene
Luciferase reporter plasmids and some of the Gal4 fusion genes have been described previously [8] . Gal4-BAZF(Mid27aa) was constructed as follows: the Mid27aa (532^612) fragment was obtained by polymerase chain reaction (PCR) using pairs of primers speci¢c for BAZF sequence linked to an EcoRI site (underlined). Primer sequences: 5P-TTT-GAATTCATGGGTTCCACAGCGGCCCCA-3P, 5P-TTTGAATTCACACGCCTGGACTACGTGTT-3P. The PCR products were subcloned in pGEM-T vector (Promega). An EcoRI fragment of the PCR products was subcloned into the EcoRI site of pSG424 carrying the Gal4(1^147) coding sequence [33] . Translation termination was provided by three-frame termination codons in pSG424. PCR-derived products as well as subcloning junctions were veri¢ed by sequence analysis. Gal4-Bcl6(Mid) was constructed as follows: the fragment of Bcl6(Mid) (566^1561) was obtained by PCR with following primers: 5P-AAAGGATCCATGCCACTGAGAAA-TACTCCC-3P with a BamHI site and an ATG start codon (underlined) and 5P-TTTGAATTCGAA-GAAGGTCCCATTCTCA-3P with a new EcoRI site (underlined). An EcoRI fragment of the PCR products was subcloned into the EcoRI site of pSG424 carrying the Gal4(1^147) coding sequence. Translation termination was provided by three-frame termination codons in pSG424. For construction of Gal4-Bcl6(Mid)(17aa3), a fragment without the BTB/POZ domain of Bcl6 (499^1082) was obtained by PCR with following primers: 5P-AAAGGATC-CATGCCACTGAGAAATACTCCC-3P with a new BamHI site and a start codon (underlined) and 5P-AGTCTAGAAAGGATGCAGGCGTTCTTGCT-3-P) with a new XbaI site (underlined). The Bcl6 fragment (1162^1561) was made by PCR. The sequence (5P-AATCTAGAAGCCTCAATCAGAATGCC-3P) with a new XbaI site (underlined) was synthesized as a primer. A XbaI^SpeI fragment was subcloned into the XbaI site of the fragment of Bcl6 without BTB/ POZ domain (499^1082) in pGEM-T Easy vector, then the EcoRI fragment of Bcl6(Mid)(17aa3) was subcloned into the EcoRI site of pSG424. PCR-derived products as well as subcloning junctions were veri¢ed by sequence analysis.
NIH3T3 cells were cultured in Dulbecco's modi¢ed Eagle's medium (DMEM, Life Technologies) plus 10% fetal calf serum (FCS; Sigma) containing penicillin G (100 U/ml) and streptomycin (100 Wg/ ml). NIH3T3 cells were plated at 3.3U10 5 cells per 60-mm-diameter dish 1 day before transfection. Various expression plasmids, p5GBS luc (luciferase re-porter plasmid) (0.5 Wg), and pRL-tk (0.05 Wg) (Promega) or pRL-SV40 (0.5 Wg) (Promega) as a transfection e¤ciency control in 6 Wl of Lipofectamine (Gibco BRL) in 2 ml of Opti-MEN (Gibco BRL) were cotransfected into NIH3T3 cells for 8 h. Transfected cells were cultured with DMEM with 10% FCS for 24 h, and then further cultured with Trichostatin A (TSA) (150 nM; Biomol) for 24 h. Luciferase activity in cell lysates was determined by standard methods with Pikkagene Dual (ToyoInk).
Construction of Bcl6 expression vectors
Bcl6 expression plasmids were constructed as follows. pcDNA3-Bcl6: a BamHI fragment of Bcl6 was inserted into pcDNA3 (Invitrogen). pcDNA3-Bcl6(POZ3) (Bcl6 without the BTB/POZ domain): a 670 base pairs (bp) fragment of pcDNA3-Bcl6 (566^1217) was obtained by PCR with following primers: 5P-AAAGGATCCATGCCACTGAGAAA-TACTCCC-3P with a BamHI site and an ATG start codon (underlined) and 5P-AAAAGGGTAGGCTC-GAGGGGAGAGGCGACC-3P with a XhoI site (underlined). An EcoRI^XhoI fragment of PCR products in pGEM-T vector was subcloned into the EcoRI^XhoI site of pcDNA3-Bcl6 to replace the BTB/POZ domain. pcDNA3-POZ: a fragment containing the BTB/POZ domain of Bcl6 (1^520) cDNA was obtained by PCR with following primers linked to an EcoRI site (underlined): 5P-TTTGAATT-CATGGCCTCCCCGGCTGACA-3P and 5P-TTT-GAATTCGAAGAAGGTCCCATTCTCA-3P. An EcoRI fragment of PCR products in pGEM-T vector was subcloned into the EcoRI site of pcDNA3. pcDNA3-Bcl6(POZ3,17aa3) (Bcl6 deleted with the BTB/POZ domain and the 17aa sequence): a fragment without the BTB/POZ domain of Bcl6 (4991 082) was obtained by PCR with following primers: 5P-AAAGGATCCATGCCACTGAGAAATACTC-CC-3P with a new BamHI site and a start codon (underlined) and 5P-AGTCTAGAAAGGATGCAG-GCGTTCTTGCT-3P) with a new XbaI site (underlined). PCR products were subcloned into pGEM-T vector. A BamHI^EcoRI fragment of pcDNA3-Bcl6 (POZ3) replaced the BamHI^EcoRI fragment of pcDNA3-Bcl6. The Bcl6 fragment (1162^1784) was made by PCR. The sequence (5P-AATCTAGA-AGCCTCAATCAGAATGCC-3P) with a new XbaI site (underlined) was synthesized as a primer. A XbaI^EcoRI fragment of PCR products was subcloned into the XbaI^EcoRI site of pcDNA3-Bcl6(POZ3) to make pcDNA3-Bcl6(POZ3,17aa3). MSCV/Bcl6-IRES-EGFP: pcDNA3-Bcl6 was digested with BamHI and SphI, then this Bcl6 fragment was cloned into the BamHI^SphI site of pREV-TRE vector (Clonech). The resulting pREV-TRE-Bcl6 was digested with BamHI and HpaI, and the BamHI site of this fragment was blunted. The 2166 bp BamHI (blunted)^HpaI fragment was then cloned into the HpaI site of MSCV/IRES-EGFP (gifts from Dr. A. Kume, Jichi Medical School, Tochigi, Japan) [34] . pcDNA3-Bcl6-ER: the EcoRIB glII fragment without stop codon (about 330 bp) in Bcl6 cDNA was obtained by PCR. PCR products were inserted in pGEM-T vector (pGEM-Bcl6). pMV-7-myc-ER (gifts from Dr. E. Bossy-Wetzel, Institute Pasteur, France) [26] was digested with Bam-HI. The resulting 954 bp fragment, containing a part of the human estrogen receptor (ER) gene, was cloned into the BglII site of pGEM-Bcl6. The resulting Bcl6-ER gene was digested with EcoRI and the 1284 bp fragment was subcloned into the EcoRI site of pcDNA3. pcDNA3-Bcl6(POZ3)-ER: the EcoRIX hoI fragment of pcDNA3-Bcl6(POZ3) was subcloned into the EcoRI^XhoI site of pcDNA3-Bcl6-ER to replace the BTB/POZ domain. All PCR-derived products as well as subcloning junctions were veri¢ed by DNA sequence.
Immunoblot analysis
NIH3T3 cells were transiently transfected with pcDNA3-Bcl6, pcDNA3-Bcl6(POZ3), pcDNA3-Bcl6(POZ3,17aa3) or pcDNA3 control vector. Bcl6 protein in transfectants was detected by immunoblot analysis [21] . Brie£y, cells were lysed in IP bu¡er 24 h after transfection. Aliquots of cell lysate were reacted with 2 Wg of anti-Bcl6 antibody (C-19: sc-368, Toyobo) for 1 h at 4³C. Immune complexes were precipitated with protein G-Sepharose beads (Zymed) for 2 h at 4³C. Immunoprecipitates were washed three times with IP bu¡er, analyzed by sodium dodecyl sulfate^polyacrylamide gel electrophoresis and transferred to a polyvinyl di£uoride membrane (Immobilon-P, Millipore). Blots were incubated with rabbit anti-Bcl6 antibody [20] fol-lowed by horseradish peroxidase conjugated donkey anti-rabbit immunoglobulin (Amersham) for 1 h at each step, and developed with enhanced chemiluminescence reagents (Amersham International).
Generation of Bcl-x L transfected cell lines
The XbaI fragment of rat Bcl-x L cDNA was subcloned into an XbaI site of the plasmid pEF-BOS, which harbors an elongation factor 1K promoter (gifts from Dr. S. Ohta, Nippon Medical School, Kawasaki, Japan) [35] . pEF-BOS/Bcl-x L (20 Wg) was transfected into NIH3T3 with 1 Wg of pSTneoB, which carries a neomycin-resistant gene [36] . Transfection was performed by electroporation with a Gene Pulser (Bio-Rad) at 0.23 kV in a 0.4-cm cell. After selection with 0.5 mg/ml geneticin G418 (Life Technologies), two clones that stably expressed the exogenous Bcl-x L gene were established. Clone 26^11 and 26^9 expressed the highest and the lowest level of Bcl-x L mRNA among transfectants, respectively (data not shown). Parental NIH3T3 cells as well as two NIH3T3 clones transfected with pST-neoB (neo-1 and neo-2) were used as controls. Cell morphology, proliferative behavior and expression of Bcl-2 and Bax mRNA were comparable between Bcl-x L transfectants and parental NIH3T3 (data not show).
Transient transfection assay and X-gal staining
NIH3T3 cells were seeded at a density of 1U10 6 cells per 6 cm dish in DMEM. Total 2 Wg of pcDNA3 and pcDNA3-Bcl6 were co-transfected with 0.2 Wg of a L-galactosidase expression vector (RSV-L-gal) using Lipofectamine. Cells were rinsed twice with PBS 12 h after transfection, and further cultured with DMEM containing 10% FCS for 12 h. To identify L-gal activity, cells were ¢xed with 1% glutaraldehyde in PBS for 5 min at room temperature, washed twice with PBS and stained with X-gal solution (0.5 mg/ml 5-chromo-4-chloro-3-indoxyl L-gal, 3 mM K 3 Fe(CN) 6 , 3 mM K 4 Fe(CN) 6 . 3H 2 O, 1 mM MgCl 2 , 10 mM KCl, 0.1% Triton X-100 in PBS). For transient transfection death assay [37] , NIH3T3 cells were seeded at a density of 3U10 5 cells per 6 cm dish in DMEM without phenol red and 10% activated-charcoal-treated FCS. Total 0.5 Wg of pcDNA3 and pcDNA3-Bcl6-ER or pcDNA3-Bcl6 were cotransfected with 1.5 Wg of RSV-L-gal using Lipofectamine. Cells were rinsed twice with PBS 12 h after transfection, and further cultured with DMEM containing 10% FCS for 20 h. Cells were lysed in 500 Wl of lysis bu¡er containing 25 mM Tris^HCl (pH 7.8), 2 mM dithiothreitol, 10% glycerol, 1 mM EDTA, and 1% Triton X-100. Samples (20 Wl) were then analyzed for L-gal activity as described. Percent cytotoxicity is calculated with the formula: Percent cytotoxicity = 1003(experimental L-gal/medium control L-gal)U100.
Flow cytometric analysis
Cell DNA analysis was performed as described by Lamm et al. [38] . Brie£y, NIH3T3 cells were transfected with Bcl6-EGFP (15 Wg) or EGFP (15 Wg) using Lipofectamine. Then, cells were cultured with DMEM with 10% FCS for 16 h. Cells were resuspended in 300 Wl of PBS and added 5 ml of ice-cold 75% ethanol drop-wise under agitation. Cell pellets were washed twice with PBS and then resuspended in PBS containing 50 Wg/ml propidium iodide and 50 Wg/ml DNase-free RNase A (Roche Molecular Biochemicals). Cells were incubated for 1 h on ice and then analyzed DNA content on a FACSCalibur (Becton Dickinson) using Cell Quest software (Becton Dickinson) for Macintosh (Apple Computer).
Results
The 17aa region in the middle portion of Bcl6 and BAZF expresses transrepressor activity by recruiting HDACs
To examine repressor activity of the 17aa region of Bcl6 and BAZF, the Gal4-fusion gene of Bcl6 or BAZF and p5GBS luc that carries the luciferase reporter gene with Gal4-binding DNA sequence were cotransfected into NIH3T3 cells. Fig. 1 shows that repressor activity of Gal4-Bcl6 (Fig. 1A) and Gal4-BAZF (Fig. 1B) associated with the BTB/POZ domains and the middle portion. However, the Gal4-Bcl6(Mid)(17aa3) and Gal4-BAZF(Mid)(17aa3) genes that encode the middle portion lacking the 17aa region lost repressor activity. Furthermore, Gal4-BAZF(Mid27aa) that encodes 27aa including the 17aa region expressed the activity, indicating that the 17aa region is likely to be a novel activity domain of transcriptional repressors.
Since the corepressor SMRT binds to the BTB/ POZ domain of Bcl6 [9] , the repressor activity of Bcl6 may be explained by remodeling of the chromatin structure by recruiting a complex of SMRT, mSI-N3A and HDAC1 [13, 14] . To address the functional relevance of the ability of the 17aa region in the middle portion of Bcl6 and BAZF to recruit a HDAC complex, we examined whether the addition of an inhibitor of HDACs in the culture could block Gal4-BAZF(Mid27aa)-mediated transcriptional repression or not. TSA is a potent and speci¢c inhibitor of HDAC activity and is active in nanomolar concentration [39] . The addition of TSA (150 nM) inhibited Bcl6-and BAZF-mediated transcriptional repression. Furthermore, the BTB/POZ-mediated and the BAZF(Mid27aa)-mediated transcriptional repression also decreased by the addition of TSA. These results suggest that the 17aa region in the middle portion of Bcl6 and BAZF can recruit HDACs to express transrepressor activity.
Overexpression of Bcl6 in NIH3T3 cells induces apoptosis
When the Bcl6 gene was transfected into NIH3T3 cells, we could not make any stable transfectants, suggesting induction of cell death by Bcl6 overexpression. To examine the inducibility of cell death, pcDNA3-Bcl6 and RSV-L-gal were transiently cotransfected into NIH3T3 cells. When L-gal activity in transfectants was histochemically detected by X-gal staining, many of the blue stained cells exhibited shrunken cell shape, condensed chromatin and cytoplasmic blebs ( Fig. 2A) , suggesting cell death by apoptosis. By contrast, transfection with pcDNA3 and RSV-L-gal revealed mainly normal and healthy looking blue stained cells. Furthermore, we con¢rmed the induction of cell death in NIH3T3 cells by the transient transfection death assay. Various amounts of expression vectors (pcDNA3 and pcDNA3-Bcl6) were cotransfected with a L-gal expression vector into NIH3T3 cells. The cells were harvested 24 h after transfection, and L-gal activity in survived cells was analyzed. Cytotoxicic activity was related with the amount of Bcl6 transfected (Fig. 2B) . We next con¢rmed that a type of the cell death was apoptosis by measuring the amount of DNA content in dying cells [38, 40] . NIH3T3 cells were transfected with MSCV-Bcl6/IRES-EGFP, and DNA in those cells was stained with propidium iodide 24 h after transfection. Apoptosis of transiently transfected cells was detected by £ow cytometry (Fig. 2C) . Percentage of apoptotic (subdiploid) cells in MSCV-Bcl6/IRES-EGFP transfectants was substantially larger than that in control although cell cycle patterns from G1 to G2/M phase was similar between them. These results indicate that overexpression of Bcl6 induces apoptosis in NIH3T3 cells.
Transrepressor activity of Bcl6 has been mapped Fig. 3 shows that apoptosis was induced in NIH3T3 cells transfected with either pcDNA3-POZ or pcDNA3-Bcl6(POZ3). POZ-mediated apoptosis reached to the plateau level of cytotoxicity (within 12 h) 12 h earlier than Bcl6(POZ3)-mediated cell death did (within 24 h). Furthermore, the plateau level (70%) of POZ-mediated cytotoxicity was lower than that (90%) of Bcl6(POZ3)-mediated apoptosis (Fig. 3B) .
Overexpression of Bcl-x L inhibits apoptosis in many experimental systems [41, 42] . E¡ect of Bcl-x L overexpression on the POZ-mediated and the Bcl6(POZ3)-mediated apoptosis was analyzed by the transient transfection death assay. Bcl-x L transfectants and control cells were transiently transfected with pcDNA3-POZ or pcDNA3-Bcl6(POZ3). As presented in Fig. 4 , high ( s 70%) cytotoxicity was induced in control NIH3T3 cells transfected with pcDNA3-Bcl6, pcDNA3-POZ or pcDNA3-Bcl6(POZ3). Overexpression of Bcl-x L could not rescue cell death induced by overexpression of Bcl6 or Bcl6(POZ3). In contrast, cytotoxicity mediated by overexpression of the BTB/POZ domain (pcDNA3-POZ) decreased to 40% in Bcl-x L transfectants.
Overexpression of Bcl6(POZ3) induces apoptosis by recruiting HDACs
To elucidate the molecular mechanism of Bcl6(POZ3)-mediated apoptosis, NIH3T3 cells were transfected with pcDNA3-Bcl6(POZ3)-ER that encodes Bcl6(POZ3) and ER fusion protein.
Since ER was fused to the zinc ¢nger domain in the 3P side of Bcl6(POZ3), ER may inhibit Bcl6(POZ3) from moving into the nucleus as previously reported [43] . Those transfected cells were cultured in the presence or absence of L-estradiol, and the cell death was determined by the transient transfection death assay. When Bcl6(POZ3)-ER transfectants were cultured without L-estradiol, cytotoxicity was not detected ( 6 10%) (Fig. 5) . By contrast, the addition of L-estradiol in the cultures of Bcl6(POZ3)-ER transfectants induced cytotoxicity to 43%. These data suggest that localization of Bcl6(POZ3) in the nucleus is important to induce apoptosis.
Since the 17aa region in the middle portion of Bcl6(POZ3) was critical for expressing repressor ac- tivity, we examined a role of the 17aa region in the induction of apoptosis by the transient transfection death assay using pcDNA3-Bcl6(POZ3,17aa3) encoding Bcl6(POZ3) lacking the 17aa region. Those gene products were detected in transfectants by immunoblot analysis (Fig. 6A) . Cytotoxicity by Bcl6(POZ3,17aa3) overexpression was signi¢cantly lower than that by overexpression of Bcl6(POZ3) (Fig. 6B) . Furthermore, we tried to block Bcl6(POZ3)-mediated apoptosis by the addition of TSA in the culture (Fig. 6C) . More than 50 nM of TSA largely inhibited cell death mediated by over- expression of Bcl6(POZ3). However, these doses of TSA did not a¡ect viability of cells transfected with pcDNA3-Bcl6(POZ3,17aa3).
Discussion
The 17aa sequence (aa 370 to aa 386) of Bcl6 is 100% identical to that (aa 188 to aa 204) of BAZF [8] . We have mapped the repressor domain of Bcl6 and BAZF to a minimal 27aa sequence including the 17aa region that is su¤cient to repress transcription of the luciferase reporter gene with Gal4-binding DNA sequence when Bcl6 and BAZF were fused to a Gal4 DNA-binding domain. The 17aa sequence has no homology to the known activity site of transcriptional factors, and may perhaps be a novel activity domain of transcriptional repressors. Since the 17aa-mediated transcriptional repression can be overcome by the addition of TSA in the culture, the 17aa region may have the ability to repress transcription by recruiting HDACs. One possibility of the mechanism to recruit HDACs by the 17aa region of Bcl6 is a binding of the 17aa region to HDACs, as illustrated by the cases of both Rb [44^46] and YY-1 [47] . As HDACs can make a complex with SMRT and mSIN3A [13, 14] , the other possibility is that the 17aa region of Bcl6 may associate with some part of a SMRT/mSIN3A/HDAC complex. Recent results showed that the middle portion (aa 191 to aa 383) of Bcl6 is able to associate with mSIN3A [12] . However, a further N-terminally truncated Bcl6 derivative (aa 265 to aa 383) lost its ability to interact with mSIN3A. So the 17aa sequence (aa 370 to aa 386) in the middle portion of Bcl6 may associate with a part of SMRT/mSIN3A/HDAC complex except mSIN3A. The BTB/POZ domain of Bcl6 interacts with SMRT [9^12]. Thus, the BTB/POZ domain, the front half (aa 191 to aa 264) and the 17aa region (aa 370 to aa 386) in the middle portion of Bcl6 may bind to di¡erent part of the SMRT/mSIN3A/HDAC complex to recruit it to target genes.
Overexpression of Bcl6(POZ3) in ¢broblasts was evaluated using the transient transfection death assay and induced apoptosis. Since overexpression of Bcl6(POZ3,17aa3) could not induce apoptosis, the 17aa region is critical for induction of apoptosis. The addition of TSA in the culture inhibited Bcl6(POZ3)-mediated apoptotic cell death. Thus, overexpression of Bcl6(POZ3) may recruit a SMRT/mSIN3A/HDAC complex to induce apoptosis. When we used Bcl6(POZ3)-ER fusion protein, apoptosis was enhanced by the addition of L-estradiol in the culture, suggesting that nuclear localization of Bcl6(POZ3) is important for induction of apoptosis. Thus, overexpression of Bcl6(POZ3) may recruit a SMRT/mSIN3A/HDAC complex to target genes to repress their expression and induce apoptosis. This mechanism appears to be shared by other POZ/zinc ¢nger-type transcriptional repressors [48^53] . Although the previous report [23] suggest that the cooperative down-regulation of Bcl-x L and up-regulation of Bax may explain the mechanism of Bcl6-mediated apoptosis in CV-1 cells, overexpression of Bcl-x L cannot rescue Bcl6(POZ3)-mediated cell death in NIH3T3 cells, suggesting that Bcl-x L is not a target gene.
Another interpretation of the mechanism is that overexpression of Bcl6(POZ3) modulates HDAC function in NIH3T3 cells by forming a SMRT/mSI-N3A/HDAC complex. This interpretation may explain the mechanism of cell death induced by overexpression of the BTB/POZ domain since the BTB/ POZ domain of Bcl6 does not contain the DNAbinding zinc-¢nger motifs. The BTB/POZ domain is an evolutionary conserved domain often found in developmentally regulated transcription factors. The BTB/POZ domain of Bcl6 and BAZF has homology to NH2-terminal regions of some zinc ¢nger-type DNA-binding proteins, such as the Drosophila tramtrack and human KUP protein. This shared domain is important for speci¢c protein-protein interactions. Repressor activity of Bcl6 associates with the BTB/ POZ domain like as other POZ/zinc ¢nger-type DNA-binding proteins including ZF5 and PLZF. The BTB/POZ domain of PLZF has been shown to interact with SMRT [47] , mSIN3A and HDAC 1 [50] , indicating that PLZF is also able to recruit a SMRT/mSIN3A/HDAC complex to target genes to repress their expression. The crystal structure of the BTB/POZ domain of PLZF reveals that the BTB/ POZ domain is a tightly interwound dimmer which may be important for POZ^POZ interactions, as well as surface features in the dimmer which may be involved in interactions with other proteins [51] . The BTB/POZ domain of Bcl6 also has the capability to self-interact [11] and to hetero-interact with the BTB/ POZ domain of BAZF [8] . These results suggest that POZ-mediated cell death may be due to modulate HDAC function in NIH3T3 cells by making a large complex including a SMRT/mSIN3A/HDAC complex by the POZ-mediated protein/protein interactions.
Pathological phenotypes of Bcl6 3a3 mice suggest that Bcl6 plays a role in protection of cardiac myocytes [21] and spermatocytes [54] from cell death, and germinal center B cells require a large amount of Bcl6 for their survival [19] . Furthermore, overexpression of Bcl6 enhanced viability of di¡erentiating myocytes by preventing apoptosis [22] . However, the overexpression induced apoptosis in CV-1, HeLa [23] , DIF9 (pro-B cell line), mouse L (data not shown) and NIH3T3 cells, suggesting that function of Bcl6 is various among cell types and di¡erentiation stages. The mechanism of apoptosis induced by the overexpression may also be various among cell types. Although overexpression of Bcl6 induces cell cycle arrest at the G2/M phase and the cooperative down-regulation of Bcl-x L and upregulation of Bax in CV-1 cells [23] , the cell cycle arrest does not occur in NIH3T3 cells by overexpression of Bcl6 (Fig. 2C) and overexpression of Bcl-x L cannot rescue Bcl6(POZ3)-mediated cell death in NIH3T3 cells (Fig. 4) . Thus, the mechanism of cell death in CV-1 (SV-40 transformed monkey kidney) cells may be di¡erent from that in NIH3T3 (mouse ¢broblast) cells. These results suggest that the amount of Bcl6 in each di¡erentiation step of each type of cells is critical and inappropriate expression of Bcl6 in improper cells induces or protects apoptosis by transrepressing target genes with recruiting HDACs. This may explain mechanisms of leukemogenesis of B cells with the chromosomal translocation involving 3q27 [55] . Here we have identi¢ed a new functional domain of Bcl6 that recruits HDACs, and this domain can be a molecular target of therapy for the leukemogenesis.
